Alhainen K, Helkala E L, Reinikainen K, Riekkinen P
Department of Neurology, University of Kuopio, Finland.
J Neural Transm Park Dis Dement Sect. 1993;5(3):185-92. doi: 10.1007/BF02257673.
The effect of tetrahydroaminoacridine (THA) on the cerebrospinal fluid (CSF) monoamine metabolites was studied in 22 patients with Alzheimer's disease in an open treatment trial. The CSF monoamine metabolites were assayed at baseline and after 4 weeks' active THA treatment with 100 mg/d. A statistically significant increase in the CSF homovanillic acid (HVA) and in 5-hydroxyindoleacetic acid (5-HIAA) content was found. The increase of the CSF 5-HIAA level correlated significantly with improvement in cognitive tests and in the Instrumental Activities of Daily Living Scale. We conclude that besides its anticholinesterase activity THA enhances also the monoaminergic neurotransmission in the brain and that the clinical improvement during THA treatment may be partly mediated through the monoaminergic system.
在一项开放性治疗试验中，对22例阿尔茨海默病患者研究了他克林（THA）对脑脊液（CSF）单胺代谢产物的影响。在基线时以及接受100mg/d的THA积极治疗4周后，对CSF单胺代谢产物进行了测定。发现CSF中高香草酸（HVA）和5-羟吲哚乙酸（5-HIAA）含量有统计学意义的增加。CSF中5-HIAA水平的升高与认知测试及日常生活活动量表中的改善显著相关。我们得出结论，除了其抗胆碱酯酶活性外，THA还增强了大脑中的单胺能神经传递，并且THA治疗期间的临床改善可能部分通过单胺能系统介导。
